Peripheral T-cell lymphoma faces challenges

Share This Post

The Cleveland Clinic of the United States Eric D. His et al. Reported that the diagnosis of peripheral T cell lymphoma (PTCL) in the United States varies greatly, and often lacks important phenotypic information to fully distinguish lymphoma. Considering the upcoming World Health Organization classification, the testing gap for selected markers should be filled. Accurate diagnosis is becoming more and more important, it will bring us into the era of targeted therapy of PTCL. (Clin Lymphoma Myeloma Leuk. 2017; 17: 193-200.)

With the deepening of understanding of the unique population of peripheral T-cell lymphoma (PTCL), subtype-specific research methods continue to emerge, and accurate diagnosis becomes more and more important.

The study obtained data from the study of comprehensive treatment measures for peripheral T-cell lymphoma (COMPLETE) and conducted a methodological analysis of patients with histopathological diagnosis of PTCL. The COMPLETE study is a large prospective cohort study of patients with new-onset PTCL in the United States. The results show that 499 patients were enrolled from 40 academic institutions and 15 community centers. A baseline assessment form was collected in 493 cases, of which 435 (88%) were available for analysis. The most common diagnoses are PTCL, unspecified PTCL (PTCL-NOS), anaplastic large cell lymphoma and angioimmunoblastic T cell lymphoma (AITL). Each patient evaluated an average of 10 (0-21) markers. CD30 is routinely evaluated, but the expression of CD30 is inconsistent in patients who are not anaplastic large cell lymphoma. Only 17% of patients with PTCL-NOS evaluated PD1 expression. CXCL13 is a more sensitive indicator of AITL. The expression rate of AITL patients is 84%, but only 3% of PTCL-NOS patients have detected the expression of CXCL13. The evaluation results of follicular helper T cell markers are different among patients in academic institutions and communities. Academic institutions more often evaluate the expression of PD1 in patients with AITL (62% vs 12%, P = 0.01). 

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

PiggyBac Transposon System
AI & Technology

PiggyBac Transposon System: A Revolutionary Tool in Cancer Gene Therapy

The PiggyBac Transposon System is revolutionizing genetic engineering in cancer research, especially in CAR T-cell therapy. With its high integration efficiency and large cargo capacity, it provides a powerful, non-viral alternative to traditional gene delivery methods. Learn how PiggyBac is advancing personalized cancer treatment and shaping the future of oncology.

Breakthrough 2025 Treatments for Advanced Breast Cancer
Biotech Innovations

Breakthrough Treatments for Advanced Breast Cancer in 2025

In 2025, advanced breast cancer treatment has entered a new era. Precision medicine and targeted therapies are enabling doctors to tailor care based on genetic profiles. Immunotherapy and antibody-drug conjugates are delivering more effective tumor targeting, while experimental cellular treatments like CAR T-cell therapy show immense promise. These cutting-edge options are transforming outcomes and quality of life for patients facing metastatic breast cancer. Explore the latest innovations driving hope and progress.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

We Are Online! Chat With Us!
Scan the code